Pages that link to "Q39143622"
Jump to navigation
Jump to search
The following pages link to PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. (Q39143622):
Displaying 50 items.
- Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells (Q26751020) (← links)
- Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma (Q26766240) (← links)
- Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer (Q26852704) (← links)
- Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience (Q28068959) (← links)
- Features of Memory-Like and PD-1( ) Human NK Cell Subsets (Q28073988) (← links)
- Systemic therapy for bladder cancer finally comes into a new age. (Q30249047) (← links)
- Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients (Q33809528) (← links)
- Adjuvant therapy for renal cell carcinoma: past, present, and future (Q34005127) (← links)
- HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. (Q36799788) (← links)
- Combination immune therapies to enhance anti-tumor responses by NK cells. (Q37408550) (← links)
- PD-1 expression on the surface of peripheral blood CD4( ) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma (Q37429917) (← links)
- Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib (Q37687194) (← links)
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma (Q37687323) (← links)
- Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. (Q38497851) (← links)
- Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma (Q38720431) (← links)
- Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors (Q38730989) (← links)
- What advances have been made in immune-therapy for renal cell carcinoma? (Q38759282) (← links)
- Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions (Q38847861) (← links)
- The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies (Q38850221) (← links)
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer (Q38937417) (← links)
- Prognostic impact of PD-1 and its ligands in renal cell carcinoma (Q39255841) (← links)
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (Q39313889) (← links)
- Integrating Immunotherapy Into the Management of Renal Cell Carcinoma (Q39360604) (← links)
- NK Cell Exhaustion. (Q39431541) (← links)
- The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. (Q39538318) (← links)
- RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma. (Q41450925) (← links)
- PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients (Q41612447) (← links)
- Control of NK Cell Activation by Immune Checkpoint Molecules (Q47128718) (← links)
- Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma (Q47724348) (← links)
- Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. (Q50288120) (← links)
- NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. (Q50502690) (← links)
- Association of PDCD1 gene markers with susceptibility to thyroid cancer. (Q51273001) (← links)
- Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. (Q54511300) (← links)
- Albumin/globulin ratio is negatively correlated with PD-1 and CD25 mRNA levels in breast cancer patients. (Q55083652) (← links)
- A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease. (Q55456412) (← links)
- Immuno-Oncology: Emerging Targets and Combination Therapies (Q56889817) (← links)
- Diagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients (Q58698521) (← links)
- CD56-negative NK cells with impaired effector function expand in CMV and EBV co-infected healthy donors with age (Q61808694) (← links)
- [PD-1 expression on the surface of peripheral blood CD4 T cell and its association with the prognosis of patients with peripheral T/NK cell lymphoma] (Q88665552) (← links)
- NK Cell-Based Immune Checkpoint Inhibition (Q89965774) (← links)
- Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence (Q89967245) (← links)
- Minimal PD-1 expression in mouse and human NK cells under diverse conditions (Q90064248) (← links)
- Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? (Q90176787) (← links)
- NK Cell Dysfunction and Checkpoint Immunotherapy (Q90265781) (← links)
- Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors (Q91993897) (← links)
- Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward (Q92372110) (← links)
- Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab (Q92586148) (← links)
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (Q92608513) (← links)
- Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets (Q92625088) (← links)
- Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming (Q92845938) (← links)